ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

  • Views:

    Views Icon 3160

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023. 

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

4 sessions
Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Watch now
The PARAGLIDE-HF Trial Watch now
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Watch now
TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction Watch now

Part 2

Expert Interviews

10 sessions
MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Watch now
REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Watch now
APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis Watch now
DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction Watch now
DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF Watch now
NUDGE-FLU: Increasing Influenza Vaccination in HF Patients Watch now
DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF Watch now
TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure Watch now
Diagnosis in Heart Failure in Women Watch now
Dapagliflozin and Peripheral Arterial Disease in Heart Failure Watch now

About the episode

We are joined onsite by Dr Niklas Dyrby Johansen (Herlev and Gentofte Hospital, DK) to discuss the late-breaking results of the NUDGE-FLU trial in a cohort of patients with cardiovascular disease (CVD), originally presented at HFA's 2023 scientific sessions in Prague. 

NUDGE-FLU is a prospective, randomized, open-label implementation trial that enrolled over 96,0000 patients across Denmark. The study population included individuals who were eligible for the influenza vaccine in the Danish health system, 18 years and above. Patients were randomized into 1 of 10 study arms - one of which was a control, with 9 intervention arms. In the intervention arm, e-mail 'nudges' were sent to patients, encouraging them to receive their influenza vaccine.

Interview Questions: 
1. What is the importance of the NUDGE-FLU Trial, in the context of heart failure prevention?
2. Tell us more about the study design and cohort of patients with CVD in NUDGE-FLU?
3. How were the effects of vaccination measured against CVD patients within the trial?
4. What is the data presented at HFA 23?
5. What is the clinical significance of this data, and how can this be implemented into day-to-day practice?
6. What are the next steps?

Faculty Biographies

Niklas Dyrby Johansen

View full profile

Comments

You must be to comment. If you are not registered, you can register here.